The psoriasis drug market is fiercely competitive, and strongly held by large pharmaceutical...
- Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
- Cocrystal Pharma to study hepatitis C drug in Hong Kong
- Allergan assesses brazikumab in two clinical programmes for IBD
- Cardax doses first patient in CHASE trial for cardiovascular health drug
- Oxurion enrols first patient in Phase l trial of THR-687 for DME
Generon reports positive data from breast cancer drug trial
Generon BioMed has reported positive results from a Phase III trial of F-627 for the treatment of women with breast cancer.
Bio-Thera Solutions starts dosing in Phase I BAT4306F trial
Bio-Thera Solutions has started dosing patients in a Phase I clinical trial of BAT4306F to treat relapsed/refractory CD20-positive B-cell non-Hodgkin’s lymphoma.
Novartis reports new positive data from MONALEESA trials
Novartis has reported positive results from three pivotal Phase III MONALEESA trials evaluating kisqali (ribociclib) plus endocrine therapy in combination with endocrine therapy alone for the treatment of human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer in patients with difficult-to-treat visceral disease.
Detecting the Presence of Trace Polymorphs and Impurities
In the pharmaceutical industry, the detection of polymorph traces is one of the most important applications of powder x-ray diffraction (PXRD).
Cytokinetics doses first subject in Phase I CK-274 trial
Cytokinetics has dosed the first subject in a Phase I trial evaluating the safety and tolerability of CK-3773274 (CK-274) to treat hypertrophic cardiomyopathy (HCM).
Centrexion completes enrolment in Phase III CNTX-4975 trial
Centrexion Therapeutics has completed patient enrolment ahead of schedule in the Phase III VICTORY-1 trial assessing the safety and efficacy of CNTX-4975 for the treatment of individuals with moderate-to-severe knee osteoarthritis (OA) pain.
Exelixis and Ipsen start COSMIC-312 trial for advanced HCC
Exelixis and Ipsen have begun the Phase III COSMIC-312 trial of cabozantinib (cabometyx) in combination with atezolizumab (tecentriq) against sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC).
Daiichi Sankyo reports positive results from Phase I/II U3-1402 trial
Daiichi Sankyo has reported new positive efficacy and safety results from its ongoing Phase I/II study of U3-1402 in heavily pretreated patients with HER3-positive metastatic breast cancer.
Alkahest doses first patient in Phase II Parkinson’s drug trial
Alkahest has dosed the first subject in a Phase II clinical trial of GRF6021 to treat Parkinson’s disease associated with mild cognitive impairment or dementia.
ProQR receives FDA approval for Phase I/II QR-421a trial
ProQR Therapeutics has received approval from the US Food and Drug Administration (FDA) to begin the Phase I/II STELLAR trial of its investigational new drug (IND) QR-421a for the treatment of patients with Usher syndrome type II.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.